8-K current report · filed Nov 5, 2026

Tectonic Therapeutic, Inc. (TECX) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1TECX overview

Short answer

Tectonic Therapeutic, Inc. (TECX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Third-quarter results for the period ended September 30, 2026 announced.

Tectonic Therapeutic, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Third-quarter results for the period ended September 30, 2026 announced
  • General business update accompanying the quarterly financial release
  • Exhibit 99.1 contains the detailed results and management commentary

Item EX-99.1 · Exhibit EX-99.1

  • Q3 2026 net loss $21.3M, or $1.08 per share, versus $19.0M and $1.02 in Q3 2025
  • Cash $234.7M, including approximately $22.3M ATM proceeds, supports runway into Q1 2029 under current assumptions
  • TX2100 Phase 1a showed no serious or severe treatment-emergent adverse events, enabling HHT Phase 1b by year-end 2026
  • TX45 APEX Phase 2 topline results expected by end-January 2027, the next major clinical catalyst
  • TX45 ALPINE Phase 2a first patient dosed, with interim topline results expected in the second half of 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tectonic Therapeutic, Inc. 8-K filings

Get the next TECX 8-K as it lands

Follow TECX for push alerts, or ask the research agent what this filing means.